Drug Profile

Research programme: anti-cancer antibodies - BriaCell Therapeutics

Alternative Names: Cancer-directed antibodies - BriaCell Therapeutics

Latest Information Update: 28 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

28 May 2024 No recent reports of development identified for research development in Cancer in USA (Parenteral)
01 Dec 2022 BriaCell Therapeutics and BioStrand enters into R&D agreement for development of anti-cancer antibodies
27 Apr 2020 BriaCell Therapeutics files for patent protection with the US PTO for development and use of cancer-directed antibodies in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com